{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:29Z","timestamp":1791475529447,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data exist in NDD-CKD patients. Primary objective of this study was to retrospectively evaluate the efficacy of FCM compared with oral ferrous sulfate for the treatment of iron-deficiency anemia in a cohort of NDD-CKD patients, considering also the treatment costs. This was a monocentric, retrospective observational study reviewing 349 NDD-CKD patients attending an\u00a0outpatient clinic between June 2013 and December 2016. Patients were treated by either FCM intravenous infusion or oral ferrous sulfate. We collected serum values of hemoglobin, ferritin and transferrin saturation (TSAT) and ESAs doses at 12 and 18\u00a0months. The costs related to both treatments were also analysed. 239 patients were treated with FCM intravenous infusion and 110 patients with oral ferrous sulfate. The two groups were not statistically different for age, BMI and eGFR values. At 18\u00a0months, hemoglobin, serum ferritin and TSAT values increased significantly from baseline in the FCM group, compared with the ferrous sulfate group. ESAs dose and rate of infusion decreased only in the FCM group. At 18\u00a0months, the treatment costs, analysed per week, was higher in the ferrous sulfate group, compared with the FCM group, and this was mostly due to a reduction in ESAs prescription in the FCM group. Routine intravenous FCM treatment in an outpatient clinic of NDD-CKD patients results in better correction of iron-deficiency anemia when compared to ferrous sulfate. In addition to this, treating NDD-CKD patients with FCM leads to a significant reduction of the treatment costs by reducing ESAs use.<\/jats:p>","DOI":"10.1038\/s41598-021-86769-z","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T10:03:08Z","timestamp":1617357788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Luigi","family":"Cirillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Somma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Allinovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Bagal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Di Marcantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Antonio","family":"Dallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Ballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Claudio","family":"Dattolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"86769_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss, G. & Goodnough, L. T. Anemia of chronic disease. N. Engl. J. Med. 352, 1011\u20131023 (2005).","journal-title":"N. Engl. J. Med."},{"key":"86769_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ahj.2005.03.055","volume":"151","author":"BC Astor","year":"2006","unstructured":"Astor, B. C., Coresh, J., Heiss, G., Pettitt, D. & Sarnak, J. N. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 151, 492\u2013500 (2006).","journal-title":"Am. Heart J."},{"issue":"5","key":"86769_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","volume":"123","author":"Kassebaum","year":"2014","unstructured":"Kassebaum, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 123(5), 615\u2013624 (2014).","journal-title":"Blood"},{"key":"86769_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1159\/000321468","volume":"32","author":"L De Nicola","year":"2010","unstructured":"De Nicola, L. et al. For the SINTABLECDK Study Group. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: A prospective cohort study in outpatient renal clinics. Am. J. Nephrol. 32, 533\u2013540 (2010).","journal-title":"Am. J. Nephrol."},{"key":"86769_CR5","doi-asserted-by":"crossref","unstructured":"Del Vecchio, L., et al. For the ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group. Intravenous iron therapy and the cardiovascular system: Risks and benefits. Clin. Kidney J. sfaa212 (2020).","DOI":"10.1093\/ckj\/sfaa212"},{"issue":"4","key":"86769_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"JJV McMurray","year":"2012","unstructured":"McMurray, J. J. V. et al. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2(4), 279\u2013335 (2012).","journal-title":"Kidney Int. Suppl."},{"key":"86769_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ki.2015.189","volume":"88","author":"TB Drueke","year":"2015","unstructured":"Drueke, T. B. & Massy, Z. A. Oral or intravenous iron for anemia correction in chronic kidney disease?. Kidney Int. 88, 673\u2013675 (2015).","journal-title":"Kidney Int."},{"issue":"2","key":"86769_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semnephrol.2016.02.004","volume":"36","author":"R Pandey","year":"2016","unstructured":"Pandey, R., Daloul, R. & Coyne, D. W. Iron treatment strategies in dialysis-dependent CKD. Semin. Nephrol. 36(2), 105\u2013111 (2016).","journal-title":"Semin. Nephrol."},{"issue":"Suppl 1","key":"86769_CR9","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1111\/hdi.12560","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach, M. & Macdougall, I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial. Int. 21(Suppl 1), S83\u2013S92 (2017).","journal-title":"Hemodial. Int."},{"issue":"4","key":"86769_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40265-018-0885-7","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott, L. J. Ferric carboxymaltose: A review in iron deficiency. Drugs 78(4), 479\u2013493 (2018).","journal-title":"Drugs"},{"key":"86769_CR11","unstructured":"European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. Eur. Med. Agency 2013 EMA\/579491\/2013:1\u20133. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/IV_iron_31\/WC500151308.pdf."},{"key":"86769_CR12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton, D. et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99, 1671\u20131676 (2014).","journal-title":"Haematologica"},{"issue":"8","key":"86769_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2016.1182494","volume":"15","author":"L Del Vecchio","year":"2016","unstructured":"Del Vecchio, L. & Locatelli, F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin. Drug Saf. 15(8), 1021\u20131030 (2016).","journal-title":"Expert Opin. Drug Saf."},{"issue":"11","key":"86769_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall, I. C. et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transpl. 29(11), 2075\u20132084 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"5","key":"86769_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","volume":"26","author":"WY Qunibi","year":"2011","unstructured":"Qunibi, W. Y. et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol. Dial. Transpl. 26(5), 1599\u20131607 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"4","key":"86769_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ndt\/gft251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken, J. E. et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol. Dial. Transpl. 29(4), 833\u2013842 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"Suppl","key":"86769_CR17","first-page":"666A","volume":"20","author":"J Benjamin","year":"2009","unstructured":"Benjamin, J. & Qunibi, W. Y. Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non-dialysis dependent-CKD patients with or without ESA therapies [abstract no. SA-PO2422]. J. Am. Soc. Nephrol. 20(Suppl), 666A (2009).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"86769_CR18","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","volume":"25","author":"A Covic","year":"2010","unstructured":"Covic, A. & Mircescu, G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre, open-label, clinical study. Nephrol. Dial. Transpl. 25(8), 2722\u20132730 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"86769_CR19","first-page":"CD007857","volume":"1","author":"J Albaramki","year":"2012","unstructured":"Albaramki, J., Hodson, E. M., Craig, J. C. & Webster, A. C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 1, CD007857 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"86769_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U. & Gafter-Gvili, A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: An updated systematic review and meta-analysis. Am. J. Kidney Dis. 68(5), 677\u2013690 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"86769_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpeds.2016.09.053","volume":"180","author":"JM Powers","year":"2017","unstructured":"Powers, J. M., Shamoun, M., McCavit, T. L., Adix, L. & Buchana, G. R. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J. Pediatr. 180, 212\u2013216 (2017).","journal-title":"J. Pediatr."},{"issue":"11","key":"86769_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2326-11-4","volume":"24","author":"RA Moore","year":"2011","unstructured":"Moore, R. A., Gaskell, H., Rose, P. & Allan, J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 24(11), 4 (2011).","journal-title":"BMC Blood Disord."},{"issue":"11","key":"86769_CR23","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s10620-018-5204-3","volume":"63","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein, G. R. & Onken, J. E. Improved hemoglobin response with ferric carboxymaltose in patients with gastrointestinal-related iron-deficiency anemia versus oral iron. Dig. Dis. Sci. 63(11), 3009\u20133019 (2018).","journal-title":"Dig. Dis. Sci."},{"key":"86769_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/annonc\/mds338","volume":"24","author":"T Steinmetz","year":"2013","unstructured":"Steinmetz, T. et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann. Oncol. 24, 475\u2013482 (2013).","journal-title":"Ann. Oncol."},{"issue":"3","key":"86769_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ckj\/sfz065","volume":"13","author":"A Karaboyas","year":"2020","unstructured":"Karaboyas, A. et al. Low hemoglobin at hemodialysis initiation: An international study of anemia management and mortality in the early dialysis period. Clin. Kidney J. 13(3), 425\u2013433 (2020).","journal-title":"Clin. Kidney J."},{"key":"86769_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40620-019-00652-9","volume":"33","author":"G Toft","year":"2020","unstructured":"Toft, G. et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J. Nephrol. 33, 147\u2013156 (2020).","journal-title":"J. Nephrol."},{"key":"86769_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/CEOR.S139950","volume":"9","author":"NV Dahl","year":"2017","unstructured":"Dahl, N. V., Kaper, R. F., Strauss, W. E., Corvino, F. A. & Zivkovic, M. Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA. Clinicoecon. Outcomes Res. 9, 557\u2013567 (2017).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"86769_CR28","first-page":"127","volume":"4","author":"V Fragoulakis","year":"2012","unstructured":"Fragoulakis, V., Kourlaba, G., Goumenos, D., Konstantoulakis, M. & Maniadakis, N. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. Clinicoecon. Outcomes Res. 4, 127\u2013134 (2012).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"1","key":"86769_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3111\/13696998.2012.731458","volume":"16","author":"PD Wilson","year":"2013","unstructured":"Wilson, P. D., Hutchings, A., Jeans, A. & Macdougall, I. C. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. J. Med. Econ. 16(1), 108\u2013114 (2013).","journal-title":"J. Med. Econ."},{"issue":"4","key":"86769_CR30","doi-asserted-by":"publisher","first-page":"e0125528","DOI":"10.1371\/journal.pone.0125528","volume":"10","author":"JE Toblli","year":"2015","unstructured":"Toblli, J. E. & Di Gennaro, F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: Effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS ONE 10(4), e0125528 (2015).","journal-title":"PLoS ONE"},{"key":"86769_CR31","first-page":"5","volume":"32","author":"R Minutolo","year":"2015","unstructured":"Minutolo, R. et al. Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease. G. Ital. Nefrol. 32, 5 (2015).","journal-title":"G. Ital. Nefrol"},{"key":"86769_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/THC-151074","volume":"24","author":"X Calvet","year":"2016","unstructured":"Calvet, X. et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technol. Health Care 24, 111\u2013120 (2016).","journal-title":"Technol. Health Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86769-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:12:49Z","timestamp":1670047969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86769-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86769"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86769-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7463"}}